Product Information

Contents: FAS-L (A19) Blocking Peptide
Catalog Number: 66-P739
Sizes: 50 ug
Formulation: Each vial contains 100 μg of peptide in 0.5 ml PBS with 0.1% NaN₃ and 100 μg BSA.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.

Available Formats of This Product
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
66-P739	Blocking Peptides for anti-mouse/human/rat FAS-L polyclonal	N/A	N/A	WB

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.

Description

This is a peptide mapping near the amino terminus of rat FAS-L. FAS/APO-1 (CD95) is an important member of the tumor necrosis factor (TNF) superfamily involved in membrane-mediated apoptosis. Ligation of Fas by FAS ligand or an anti-FAS cross-linking antibody, triggers activation of the caspase cascade (1). Functional impairment of the FAS/FAS-L system is associated with the development and progression of malignancies (2). FAS gene mutations have been suggested to have a role in testicular germ cell tumors (3). Tumor cells frequently exhibit de novo expression of FAS-ligand (FAS-L), which plays a significant role in local tissue destruction, metastatic spread, and immune escape of the tumor cells (8). The apoptosis of lymphocytes, which occurs in autoimmune diseases, is usually induced by the FAS/FAS-ligand system (7). FAS is believed to be involved in various autoimmune diseases including, ulcerative colitis, Graves disease, and rheumatoid arthritis (5,7). FAS expression on gastric epithelial cells in patients infected with H. Pylori is responsible for the accelerated apoptosis of the cells (4). Serum FAS-L concentration has also been shown to be associated with atherosclerosis and inflammatory disease, in patients with hypertension (6).

Applications Reported

For research use only, not for diagnostic or therapeutic use. This blocking peptide has been reported for use in competition studies.

References

1. Lin P, Bush JA, Cheung KJ Jr, Li G. Tissue-specific regulation of Fas/APO-1/CD95 expression by p53. Int J Oncol 2002 Aug;21(2):261-4.
2. Redondo P, Solano T, VAzquez B, Bauza A, Idoate M. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma. Br J Dermatol 2002 Jul;147(1):80-6
3. Takayama H, Takakuwa T, Tsujimoto Y, Tani Y, Nonomura N, Okuyama A, Nagata S, Aozasa K. Frequent fas gene mutations in testicular germ cell tumors. Am J Pathology 2002 Aug; 161(2):635-41.
4. Hasumi K, Tanaka K, Saitoh S, Takagi A, Miwa T, Mine T, Koga Y. Roles of tumor necrosis factor-alpha-receptor type 1 and Fas in the Helicobacter pylori-induced apoptosis of gastric epithelial cells. J Gastroenterol Hepatol 2002 Jun;17(6):651-658.
5. Yukawa M, Iizuka M, Horie Y, Yoneyama K, Shirasaka T, Itou H, Komatsu M, Fukushima T, Watanabe S.Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis. Int J Colorectal Dis 2002 Mar;17(2):70-6
6. Okura T, Watanabe S, Jiang Y, Nakamura M, Takata Y, Yang ZH, Kohara K, Kitami Y, Hiwada K. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 2002 May;20(5):895-8
7. Hara H, Sato R, Ban Y. Accelerated production of nucleosome in cultured human mononuclear cells in untreated Graves' disease. Endocr J 2002 Apr;49(2):189-94
8. Reichmann E.The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002 Aug;12(4):309-15

Related Products

Cat. 14-6739 Purified anti-mouse/human/rat FAS-L polyclonal (clone Polyclonal)